{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T03:54:44Z","timestamp":1793246084734,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014206","name":"National Key Laboratory Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014206","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2018YFC2002000"],"award-info":[{"award-number":["2018YFC2002000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.intimp.2022.109660","type":"journal-article","created":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T12:38:15Z","timestamp":1673095095000},"page":"109660","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Comprehensive analysis of the tumor-promoting effect and immune infiltration correlation MAZ from pan-cancer to hepatocellular carcinoma"],"prefix":"10.1016","volume":"115","author":[{"given":"Mengmeng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiongjun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajun","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2022.109660_b0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.intimp.2022.109660_b0010","first-page":"e19274","article-title":"Hepatocellular Carcinoma in 2021: An Exhaustive Update","volume":"13","author":"Philips","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.intimp.2022.109660_b0015","unstructured":"C. Global Burden of Disease Cancer, J.M. Kocarnik, K. Compton, F.E. Dean, W. Fu, B.L. Gaw, et al., Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019, JAMA Oncol, 8 (2022) 420-444."},{"key":"10.1016\/j.intimp.2022.109660_b0020","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: An overview","author":"Ferlay","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.intimp.2022.109660_b0025","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/ijc.32723","article-title":"International trends in hepatocellular carcinoma incidence, 1978\u20132012","volume":"147","author":"Petrick","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.intimp.2022.109660_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.acr.2020.10.001","article-title":"Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification","volume":"149","author":"Chidambaranathan-Reghupaty","year":"2021","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.intimp.2022.109660_b0035","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/ijc.33313","article-title":"Is it possible to halve the incidence of liver cancer in China by 2050?","volume":"148","author":"Shi","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.intimp.2022.109660_b0040","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.3748\/wjg.v25.i19.2279","article-title":"Mechanisms of hepatocellular carcinoma progression","volume":"25","author":"Ogunwobi","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.intimp.2022.109660_b0045","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.intimp.2022.109660_b0050","first-page":"1245","article-title":"First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges, Expert Rev","volume":"15","author":"Rizzo","year":"2021","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.intimp.2022.109660_b0055","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.803133","article-title":"Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?","volume":"11","author":"Rizzo","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.intimp.2022.109660_b0060","doi-asserted-by":"crossref","first-page":"9997","DOI":"10.1038\/s41598-018-28337-6","article-title":"Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept","volume":"8","author":"De Lorenzo","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.intimp.2022.109660_b0065","doi-asserted-by":"crossref","unstructured":"A. Rizzo, M. Nannini, M. Novelli, A. Dalia Ricci, V.D. Scioscio, M.A. Pantaleo, Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis, Ther Adv Med Oncol, 12 (2020) 1758835920936932.","DOI":"10.1177\/1758835920936932"},{"key":"10.1016\/j.intimp.2022.109660_b0070","first-page":"1455","article-title":"Advances in novel systemic therapies for advanced hepatocellular carcinoma, Future","volume":"14","author":"Carloni","year":"2022","journal-title":"Med Chem"},{"key":"10.1016\/j.intimp.2022.109660_b0075","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20171668","article-title":"Revealing the alternative promoter usage of SAF\/MAZ gene by bichromatic fluorescent reporter construct","volume":"39","author":"Ren","year":"2019","journal-title":"Biosci Rep"},{"key":"10.1016\/j.intimp.2022.109660_b0080","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1074\/jbc.RA117.000333","article-title":"The MAZ transcription factor is a downstream target of the oncoprotein Cyr61\/CCN1 and promotes pancreatic cancer cell invasion via CRAF-ERK signaling","volume":"293","author":"Maity","year":"2018","journal-title":"J Biol Chem"},{"key":"10.1016\/j.intimp.2022.109660_b0085","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.2147\/OTT.S274215","article-title":"MicroRNA-29b-3p Inhibits the Migration and Invasion of Gastric Cancer Cells by Regulating the Autophagy-Associated Protein MAZ","volume":"14","author":"Zhao","year":"2021","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.intimp.2022.109660_b0090","article-title":"SIPL1, Regulated by MAZ, Promotes Tumor Progression and Predicts Poor Survival in Human Triple-Negative Breast Cancer, Front","volume":"11","author":"He","year":"2021","journal-title":"Oncol"},{"key":"10.1016\/j.intimp.2022.109660_b0095","article-title":"Roles of Myc-associated zinc finger protein in malignant tumors, Asia Pac","author":"Zheng","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.intimp.2022.109660_b0100","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1186\/s13046-019-1374-x","article-title":"MAZ promotes prostate cancer bone metastasis through transcriptionally activating the KRas-dependent RalGEFs pathway","volume":"38","author":"Yang","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.intimp.2022.109660_b0105","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/s41591-018-0057-z","article-title":"A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade","volume":"24","author":"Thommen","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.intimp.2022.109660_b0110","doi-asserted-by":"crossref","first-page":"e10835","DOI":"10.15252\/emmm.201910835","article-title":"Therapeutic targeting of circ-CUX1\/EWSR1\/MAZ axis inhibits glycolysis and neuroblastoma progression","volume":"11","author":"Li","year":"2019","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.intimp.2022.109660_b0115","doi-asserted-by":"crossref","first-page":"86420","DOI":"10.18632\/oncotarget.13416","article-title":"MYC associated zinc finger protein promotes the invasion and metastasis of hepatocellular carcinoma by inducing epithelial mesenchymal transition","volume":"7","author":"Luo","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2022.109660_b0120","first-page":"1260419","article-title":"Proteomics","volume":"347","author":"Uhlen","year":"2015","journal-title":"Tissue-based map of the human proteome, Science"},{"key":"10.1016\/j.intimp.2022.109660_b0125","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.intimp.2022.109660_b0130","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13000-020-0927-9","article-title":"Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment","volume":"15","author":"Krieger","year":"2020","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.intimp.2022.109660_b0135","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12935-019-1091-8","article-title":"Microsatellite instability: a review of what the oncologist should know","volume":"20","author":"Li","year":"2020","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.intimp.2022.109660_b0140","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1158\/0008-5472.CAN-12-1370","article-title":"Cell Miner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set","volume":"72","author":"Reinhold","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.intimp.2022.109660_b0145","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.intimp.2022.109660_b0150","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/14737140.2019.1585245","article-title":"Systemic treatment of advanced hepatocellular cancer: new hope on the horizon","volume":"19","author":"Chang Lee","year":"2019","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.intimp.2022.109660_b0155","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a036863","article-title":"New Approaches on Cancer Immunotherapy","volume":"10","author":"Cha","year":"2020","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.intimp.2022.109660_b0160","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.intimp.2022.109660_b0165","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1186\/s13046-019-1396-4","article-title":"From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma","volume":"38","author":"Fu","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.intimp.2022.109660_b0170","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115801","article-title":"Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review","volume":"22","author":"Oura","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.intimp.2022.109660_b0175","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41423-020-00572-w","article-title":"Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells","volume":"18","author":"Ruf","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.intimp.2022.109660_b0180","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/0888-7543(92)90372-Y","article-title":"High-resolution localization of 69 potential human zinc finger protein genes: a number are clustered","volume":"12","author":"Hoovers","year":"1992","journal-title":"Genomics"},{"key":"10.1016\/j.intimp.2022.109660_b0185","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1634\/theoncologist.2019-0244","article-title":"Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence","volume":"25","author":"Klempner","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.intimp.2022.109660_b0190","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.intimp.2022.109660_b0195","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s40425-019-0647-4","article-title":"Tumor mutational burden quantification from targeted gene panels: major advancements and challenges","volume":"7","author":"Fancello","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.intimp.2022.109660_b0200","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1158\/1078-0432.CCR-15-1678","article-title":"Microsatellite Instability as a Biomarker for PD-1 Blockade","volume":"22","author":"Dudley","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.intimp.2022.109660_b0205","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1101\/gr.226845.117","article-title":"Mutational signatures of DNA mismatch repair deficiency in C. elegans and human cancers","volume":"28","author":"Meier","year":"2018","journal-title":"Genome Res"},{"key":"10.1016\/j.intimp.2022.109660_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107753","article-title":"Tumor microenvironment as a therapeutic target in cancer","volume":"221","author":"Xiao","year":"2021","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.intimp.2022.109660_b0215","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.canlet.2019.11.009","article-title":"Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy","volume":"470","author":"Lei","year":"2020","journal-title":"Cancer Lett"},{"key":"10.1016\/j.intimp.2022.109660_b0220","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nri3902","article-title":"Immunological hallmarks of stromal cells in the tumour microenvironment","volume":"15","author":"Turley","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.intimp.2022.109660_b0225","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-3-319-78127-3_6","article-title":"Stromal Cells in the Tumor Microenvironment","volume":"1060","author":"Denton","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.intimp.2022.109660_b0230","doi-asserted-by":"crossref","first-page":"127ra137","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7\u2013h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.intimp.2022.109660_b0235","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.intimp.2022.109660_b0240","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922011456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922011456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T09:08:07Z","timestamp":1736413687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922011456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":48,"alternative-id":["S1567576922011456"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109660","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive analysis of the tumor-promoting effect and immune infiltration correlation MAZ from pan-cancer to hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109660","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109660"}}